Alyeska Investment Group
CRBU icon

Alyeska Investment Group’s Caribou Biosciences CRBU Stock Holding History

Alyeska Investment Group’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-125,000
Closed -$643K – 585
2024
Q1 		$643K Hold
125,000
– – ﹤0.01% 425
2023
Q4 		$716K Hold
125,000
– – ﹤0.01% 419
2023
Q3 		$598K Buy
+125,000
New +$776K ﹤0.01% 439

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's CRBU Position: Q2 2024 in Review

Alyeska Investment Group sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 125,000 shares — an estimated $643K sold.

Alyeska Investment Group first reported a position in CRBU in Q3 2023 and held it in 3 quarters. The position peaked at $716K in Q4 2023. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

  • Alyeska Investment Group reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 125,000 Caribou Biosciences shares in Q2 2024, an estimated $643K.
  • Alyeska Investment Group first reported a position in Caribou Biosciences in Q3 2023 and held it in 3 quarters.
  • Alyeska Investment Group's Caribou Biosciences position peaked at $716K in Q4 2023.
  • 140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Alyeska Investment Group's 13F filing for Q2 2024, filed 14 Aug 2024.